These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29038432)

  • 1. Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study.
    Zhang Y; Han C; Li J; Zhang L; Wang L; Ye S; Hu Y; Bai L
    Sci Rep; 2017 Oct; 7(1):13208. PubMed ID: 29038432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
    Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
    J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study.
    Du Y; Cao Q; Jiang C; Liang H; Ning Z; Ji C; Wang J; Zhou C; Jiang Z; Yu C; Li L; Zhao Y; Xu Y; Xu T; Hu W; Wang D; Cheng H; Wang G; Zhou J; Wang S; Zhang Y; Hu Z; Li X; Lu D; Zhang J; Xie H; Sun G
    Cancer Med; 2020 Jul; 9(14):5008-5014. PubMed ID: 32441892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
    Li J; Qin S; Wen L; Wang J; Deng W; Guo W; Jia T; Jiang D; Zhang G; He Y; Ba Y; Zhong H; Wang L; Lin X; Yang J; Zhao J; Bai Y; Wu X; Gao F; Sun G; Wu Y; Ye F; Wang Q; Xie Z; Yi T; Huang Y; Yu G; Lu L; Yuan Y; Li W; Liu L; Sun Y; Sun Y; Yin L; Hou Z
    BMC Med; 2023 May; 21(1):173. PubMed ID: 37147645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinoma.
    Wang Y; Zhao J; Yu H; Wang J; Zhang N; Cao B
    J Cancer Res Ther; 2021 Nov; 17(5):1234-1240. PubMed ID: 34850772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of apatinib for the treatment of gastric cancer.
    Geng R; Song L; Li J; Zhao L
    Expert Opin Drug Saf; 2018 Nov; 17(11):1145-1150. PubMed ID: 30324820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis.
    Wang J; Lin J; Wang R; Tong T; Zhao Y
    BMC Cancer; 2024 May; 24(1):603. PubMed ID: 38760737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study.
    Guo Y; Tang J; Huang XE; Cao J
    Medicine (Baltimore); 2019 Feb; 98(6):e13908. PubMed ID: 30732125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer.
    Wu Q; Fu Y; Wen W; Xi T; Zhao G
    J BUON; 2020; 25(2):987-994. PubMed ID: 32521896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial.
    Zheng Y; Yang X; Yan C; Feng R; Sah BK; Yang Z; Zhu Z; Liu W; Xu W; Ni Z; Beeharry MK; Hua Z; Yan M; Zhu Z; Li C
    Eur J Cancer; 2020 May; 130():12-19. PubMed ID: 32171104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.
    Li LH; Chen WC; Wu G
    Dis Markers; 2022; 2022():4322404. PubMed ID: 35531474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment effect of apatinib combined chemotherapy as second-line or above therapy in patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction.
    Zhang F; Yin Y; Ni T; Zhang M; Zhou Z; Sun X; Kuang W; Li P
    Pharmazie; 2020 Aug; 75(8):389-394. PubMed ID: 32758339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.
    Wu D; Liang L; Nie L; Nie J; Dai L; Hu W; Zhang J; Chen X; Han J; Ma X; Tian G; Han S; Long J; Wang Y; Zhang Z; Xin T; Fang J
    Asia Pac J Clin Oncol; 2018 Dec; 14(6):446-452. PubMed ID: 29573236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
    Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
    Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Lui A; Mulder K; Brezden-Masley C; Vickers M; Monzon J; Kennecke H; Goel R; Vos L; Ghosh S; Marginean H; Fields A; Maroun J; Spratlin J
    Invest New Drugs; 2018 Aug; 36(4):674-682. PubMed ID: 29725881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.
    Schmalenberg H; Al-Batran SE; Pauligk C; Zander T; Reichart A; Lindig U; Kleiß M; Müller L; Bolling C; Seufferlein T; Reichardt P; Kullmann F; Eschenburg H; Schmittel A; Egger M; Block A; Goetze TO
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):559-569. PubMed ID: 29285668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.
    Yamaguchi K; Fujitani K; Nagashima F; Omuro Y; Machida N; Nishina T; Koue T; Tsujimoto M; Maeda K; Satoh T
    Gastric Cancer; 2018 Nov; 21(6):1041-1049. PubMed ID: 29508095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
    Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK
    Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
    Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
    Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.